Avalo Therapeutics, Inc. (AVTX)
11.58
+0.31
(+2.75%)
USD |
NASDAQ |
Oct 19, 16:00
11.58
0.00 (0.00%)
After-Hours: 16:22
Avalo Therapeutics Gross Profit Margin (Quarterly)
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2025 | 72.88% |
| September 30, 2025 | |
| June 30, 2025 | |
| March 31, 2025 | |
| December 31, 2024 | 54.69% |
| September 30, 2024 | |
| June 30, 2024 | |
| March 31, 2024 | |
| December 31, 2023 | 0.00% |
| September 30, 2023 | -4.66% |
| June 30, 2023 | -10.11% |
| March 31, 2023 | -16.00% |
| December 31, 2022 | 30.80% |
| September 30, 2022 | 96.47% |
| June 30, 2022 | -51.69% |
| March 31, 2022 | 35.38% |
| December 31, 2021 | -215.5% |
| September 30, 2021 | 1.04% |
| June 30, 2021 | 84.77% |
| Date | Value |
|---|---|
| March 31, 2021 | -5.92% |
| December 31, 2020 | 61.04% |
| September 30, 2020 | 56.78% |
| June 30, 2020 | 64.04% |
| March 31, 2020 | 81.95% |
| September 30, 2019 | 45.70% |
| June 30, 2019 | |
| March 31, 2019 | 28.15% |
| December 31, 2018 | 33.85% |
| September 30, 2018 | -2.50% |
| June 30, 2018 | 44.49% |
| March 31, 2018 | 57.91% |
| December 31, 2017 | 53.25% |
| September 30, 2017 | 0.00% |
| June 30, 2017 | 0.00% |
| March 31, 2017 | 0.00% |
| December 31, 2016 | 0.00% |
| September 30, 2016 | 0.00% |
| June 30, 2016 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| AbbVie, Inc. | 74.71% |
| Rezolute, Inc. | -- |
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Anika Therapeutics, Inc. | 65.15% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -63.01% |
| Return on Assets | -52.25% |
| Return on Invested Capital | -62.06% |
| Return on Net Operating Assets | -914.4% |